Invesco
APGE

Invesco’s Apogee Therapeutics APGE Stock Holding History

Invesco’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.22M Buy
39,317
+554
+1% +$49.9K ﹤0.01% 2215
2026
Q1 		$3.26M Sell
38,763
-31,924
-45% -$2.32M ﹤0.01% 2342
2025
Q4 		$5.34M Buy
70,687
+41,549
+143% +$2.62M ﹤0.01% 2219
2025
Q3 		$1.16M Buy
29,138
+2,272
+8% +$86.8K ﹤0.01% 2865
2025
Q2 		$1.17M Buy
26,866
+2,556
+11% +$97.2K ﹤0.01% 2783
2025
Q1 		$908K Buy
24,310
+3,054
+14% +$118K ﹤0.01% 2876
2024
Q4 		$963K Sell
21,256
-110,910
-84% -$5.66M ﹤0.01% 2934
2024
Q3 		$7.76M Buy
132,166
+111,783
+548% +$5.36M ﹤0.01% 1978
2024
Q2 		$802K Sell
20,383
-96,290
-83% -$4.67M ﹤0.01% 3048
2024
Q1 		$7.75M Buy
116,673
+105,064
+905% +$4.59M ﹤0.01% 1962
2023
Q4 		$324K Buy
11,609
+1,917
+20% +$38.4K ﹤0.01% 3407
2023
Q3 		$206K Buy
+9,692
New +$214K ﹤0.01% 3582

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Invesco's APGE Position: Q2 2026 in Review

Invesco increased its Apogee Therapeutics (APGE) stake by 1.4% in Q2 2026, buying an estimated $49.9K and bringing the position to 39,317 shares worth $5.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2215.

Invesco first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. The position peaked at $7.76M in Q3 2024. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Invesco held 39,317 shares of Apogee Therapeutics worth $5.22M as of Q2 2026.
  • Invesco bought 554 Apogee Therapeutics shares in Q2 2026, an estimated $49.9K.
  • Apogee Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2215 holding.
  • Invesco first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Invesco's Apogee Therapeutics position peaked at $7.76M in Q3 2024.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.